![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Daewoong Bio Inc. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Ursodeoxycholic acid, Process III, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2020-134 - Rev 01
This Chemical Type CEP, issued on June 26, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1275 associated with this CEP further emphasizes